Overview of chikungunya epidemiology - who.int · Key features of transmission •Chikungunya has...

Post on 08-Aug-2019

212 views 0 download

Transcript of Overview of chikungunya epidemiology - who.int · Key features of transmission •Chikungunya has...

Overview of chikungunya epidemiology

Diana P. Rojas

Department of Biostatistics

University of Florida

November 29, 2018

Key features of transmission • Chikungunya has been identified in over 60 countries in Asia, Africa, Europe

and the Americas.

• Transmission mostly by Aedes aegypti and Aedes albopictus

• Other mosquitoes in Africa can act as efficient vectors for chikungunya: Aedes dalzieli, Aedes furcifer, Aedes taylori, Aedes africanus, and Aedes luteocephalus.

• Incubation period: 4-7 days (2-12 days).

• Infectious period humans: 7 days

• Extrinsic latent period: mean of 7 days (2 -9 days).

• Life expectancy of the mosquitos: 30 days.

Serial interval CHIKV

0 8

Viremia Up to 7 d

Mosquito feeds/acquires virus

Mosquito refeeds/transmits virus

Viremia

5

Human #1 Human #2

15 18 23

Extrinsic LP 7 days

Intrinsic IP 3-5 days (3-12 days)

Illness IP: 4-7 days

Illness

22% asymptomatic infection

CHIKV Transmission cycle

Weaver SC (2014) Arrival of Chikungunya Virus in the New World: Prospects for Spread and Impact on Public Health. PLoS Negl Trop Dis 8(6): e2921. doi:10.1371/journal.pntd.0002921

Factors associated with CHIKV transmission

• Environmental/ecological conditions

• Abundance of mosquito egg laying habitats

• Completely naïve populations

• Alternate vector(s), new ecological niches involved

• Viral genetics / mutations

• Attack rates may be explained by: • Surveillance practices • Season of CHIKV introduction into a country or a region • Vector density and activity; • Vector control measures; and lifestyle differences

Key features of transmission

Indicator Asia and La Reunion Americas

R0 3.0-4.2 2-4

Attack Rate % 16.55 – 55.6 % 41%

% Asymptomatic infections 3-22% 10-58.3%

Overall seroprevalence 38.2 – 75% 13-90%

CFR <1% <1%

At risk groups Newborns, >55 and comorbidities

>45 and comorbidities

Persisting CHIKV disease 48.7% 45%

Re-emergence of Chikungunya 2004-2015

Weaver SC (2014) Arrival of Chikungunya Virus in the New World: Prospects for Spread and Impact on Public Health. PLoS Negl Trop Dis 8(6): e2921. doi:10.1371/journal.pntd.0002921

1,469,912 reported cases up to December 2016. Incidence rates: 999.13 per 1,000 inhabitants.

https://www.paho.org/hq/images/stories/AD/HSD/IR/Viral_Diseases/Chikungunya/CHIKV-Data-Caribbean-2017-EW-51.jpg?ua=1

COMPORTAMIENTO DENGUE – CHIK – ZIKA, años 2008-2017*

Arbovirus transmission Colombia

Arbovirus transmission Brazil

0

2000

4000

6000

8000

10000

12000

14000

16000

18000

20000

0

20000

40000

60000

80000

100000

120000

ZIKV

and

CH

KV c

ases

DEN

V c

ases

Confirmed cases - DENV, CHKV, ZIKV in Brazil

DENV

CHKV

ZIKV

CHIKV outbreaks and current transmission

Countries with current CHIKV transmission in LA

2017: France and Italy

2018: Kenya and Sudan

https://www.paho.org/hq/dmdocuments/2017/2017-dec-22-phe-CHIKV-cases-ew-51.pdf http://www.who.int/emergencies/diseases/chikungunya/en/

Brazil Salvador: 57.1% (Dias JP et al., 2018) Mato Grosso: 20% (Cunha RV et al, 2017)

Nicaragua Managua: 13.1% (Kuan et al., 2016)

Grenada: 86% (Macpherson et al., 2016)

Saint Martin: 17% (Gay et al., 2016)

Seroprevalence studies in the Americas

La Reunion: 40% (Gerardin P. et al., 2008)

Bangladesh: 80% (Khatun et al., 2015) India: 48% (Kawle et al., 2017)

Singapore: 1.9% (Ang LW et al., 2017)

Benin: 36.1% (Sambri et al., 2015)

Mozambique: 26.4% (Gudo et al., 2015)

Western Cameroon: 51% (Demanou et al., 2010)

Malaysia: 5.9% – 55.6% (Azami et al., 2013; Said MA et al., 2010)

Kenya 7.1%

Mayotte: 37.2% (Sissoko, 2008) Grande Comore Island: 63% (Sergon et al., 2007)

French Polynesia, 2014–2015: 76%

Conclusions

• Chikungunya virus has endemic transmission in some countries in Latin America and Southeast Asia.

• CHIKV transmission is heterogenous between and within countries and regions.

• More seroprevalence studies for CHIKV are needed to understand better the impact of previous outbreaks and endemic circulation.

• The estimated R0 of CHIKV is from 2-4: attack rates 16-55%.

• The real burden of CHIKV is unknown.